Hypertension Clinical Trials Pipeline Analysis: 90+

New York, USA, Oct. 03, 2022 (GLOBE NEWSWIRE) — Hypertension Clinical Trials Pipeline Analysis: 90+ Companies are Working to Improve the Treatment Space | DelveInsight

As per a statement of World Health Organization (WHO), Hypertension is one of the silent killers in 21st century and is one of the biggest global public health concerns. Factors like technological advancement, a growing aging population, and people affected by diabetes, and high blood pressure are favoring the market. Some of the key players contributing to the worldwide anti-hypertensive medication market include Quantum Genomics, Nicox, Santen Pharmaceuticals, Ionis Pharmaceuticals, United Therapeutics Corporation, and several others.

DelveInsight’s ‘Hypertension Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline hypertension therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the hypertension pipeline domain.

Key Takeaways from the Hypertension Pipeline Report

• DelveInsight’s hypertension pipeline report depicts a robust space with 90+ active players working to develop 100+ pipeline therapies for hypertension treatment. 
• Key hypertension companies such as Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Ionis Pharmaceuticals, Future Medicine, Pharmosa BioPharm, Aerovate Therapeutics, Novartis, Cereno Scientific AB, Torrent Pharmaceuticals Limited, JeniVision, Inc., Merck Sharp & Dohme LLC, AbbVie, Acceleron Pharma Inc., Hanmi Pharmaceutical Company Limited, Gossamer Bio Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Insmed Incorporated, Gmax Biopharm LLC., Altavant Sciences GmbH, Bayer, Respira Therapeutics, Inc., Aadi Bioscience, Inc., Boehringer Ingelheim, JW Pharmaceutical, PRM Pharma, LLC, PolyActiva Pty Ltd, pH Pharma, Nicox Ophthalmics, Inc., Ocular Therapeutix, Inc., Santen SAS, Whitecap…